Company research
AN2 Therapeutics, Inc.
CIK 1880438Updated Nov 10, 2026
SecurityANTX · NASDAQ · equity
ANTX price & chart
Loading TradingView…
NASDAQ:ANTX on TradingView ↗About the company
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform. For more information please visit our website at www.an2therapeutics.com.
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) ↗
Seeking Alpha
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver ↗
AN2 Therapeutics appoints biotech veteran Cameron Trenor as CMO ↗
AN2 rises after early-stage trial data for Chagas disease therapy ↗
SEC disclosures
AN2 Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
4 filing
144 filing
Show 5 more recent filings
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 67,235,000Source | 97,689,000Source | 81,676,000Source | 75,825,000Source | 108,481,000Source | 87,491,000Source | 81,343,000Source | 121,260,000Source | 61,950,000Source | 92,087,000Source | 138,744,000Source | 102,560,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,003,000Source | 33,504,000Source | 44,318,000Source | 18,220,000Source | 26,769,000Source | 53,487,000Source | 19,985,000Source | 24,693,000Source | 19,941,000Source | 21,351,000Source | 15,647,000Source | 27,219,000Source |
| Assets, CurrentUSD | 64,016,000Source | 97,689,000Source | 79,991,000Source | 67,524,000Source | 107,438,000Source | 87,491,000Source | 69,559,000Source | 116,313,000Source | 59,937,000Source | 86,262,000Source | 110,507,000Source | 98,621,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,095,000Source | 4,263,000Source | 1,604,000Source | 4,608,000Source | 2,898,000Source | 2,203,000Source | 2,499,000Source | 2,103,000Source | 1,936,000Source | 2,644,000Source | 3,212,000Source | 2,509,000Source |
| Other Assets, NoncurrentUSD | 0Source | — | 216,000Source | 0Source | 1,043,000Source | — | 304,000Source | 1,043,000Source | 0Source | 804,000Source | 1,043,000Source | 720,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,858,000Source | 10,017,000Source | 5,755,000Source | 6,983,000Source | 10,127,000Source | 5,732,000Source | 8,014,000Source | 10,663,000Source | 8,890,000Source | 10,238,000Source | 14,043,000Source | 7,188,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 292,553,000Source | 285,814,000Source | 335,107,000Source | 291,704,000Source | 283,888,000Source | 332,742,000Source | 289,706,000Source | 281,616,000Source | 293,953,000Source | 287,594,000Source | 278,881,000Source | 185,469,000Source |
| Retained Earnings (Accumulated Deficit)USD | -232,240,000Source | -198,254,000Source | -259,163,000Source | -222,887,000Source | -185,507,000Source | -250,978,000Source | -216,425,000Source | -171,072,000Source | -240,950,000Source | -205,776,000Source | -154,455,000Source | -89,723,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 64,000Source | 112,000Source | -23,000Source | 25,000Source | -27,000Source | -5,000Source | 48,000Source | 53,000Source | 57,000Source | 31,000Source | 275,000Source | -374,000Source |
| Stockholders' Equity Attributable to ParentUSD | 60,377,000Source | 87,672,000Source | 75,921,000Source | 68,842,000Source | 98,354,000Source | 81,759,000Source | 73,329,000Source | 110,597,000Source | 53,060,000Source | 81,849,000Source | 124,701,000Source | 95,372,000Source |
| Liabilities and EquityUSD | 67,235,000Source | 97,689,000Source | 81,676,000Source | 75,825,000Source | 108,481,000Source | 87,491,000Source | 81,343,000Source | 121,260,000Source | 61,950,000Source | 92,087,000Source | 138,744,000Source | 102,560,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | 10,017,000Source | 5,585,000Source | — | — | 5,562,000Source | — | — | 8,720,000Source | — | 14,043,000Source | 7,186,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 53,000Source |
| Accounts Payable, CurrentUSD | 2,226,000Source | 1,711,000Source | 1,967,000Source | 2,113,000Source | 1,885,000Source | 2,615,000Source | 3,073,000Source | 2,433,000Source | 3,021,000Source | 3,317,000Source | 2,676,000Source | 2,122,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 170,000Source | — | — | 170,000Source | — | — | 170,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,705,000Source | 4,921,000Source | 1,747,000Source | 2,954,000Source | 5,843,000Source | 1,767,000Source | 4,043,000Source | 6,914,000Source | 2,052,000Source | 4,454,000Source | 6,681,000Source | 2,837,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 99,300,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,028,000Source | -10,649,000Source | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,460,000Source | 2,047,000Source | 6,246,000Source | 8,338,000Source | 8,412,000Source | 4,391,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -405,000Source | -244,000Source | -296,000Source | 641,000Source | 553,000Source | 2,497,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,073,000Source | -10,624,000Source | -29,834,000Source | -49,257,000Source | -53,288,000Source | -33,462,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 8,290,000Source | 9,193,000Source | 28,311,000Source | 54,589,000Source | -43,278,000Source | -21,771,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 37,329,000Source | 65,000Source | 113,000Source | 372,000Source | 84,994,000Source | 70,355,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 33,546,000Source | -1,366,000Source | -1,410,000Source | 5,704,000Source | -11,572,000Source | 15,122,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 18,003,000Source | 33,504,000Source | 44,318,000Source | 18,220,000Source | 53,487,000Source | 19,985,000Source | 19,941,000Source | 21,351,000Source | 15,647,000Source | 27,219,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 801,000Source | 1,902,000Source | 972,000Source | 1,998,000Source | 1,460,000Source | 2,047,000Source | 6,246,000Source | 8,338,000Source | 8,412,000Source | 4,391,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 99,300,000Source |
| General and Administrative ExpenseUSD | — | — | 3,040,000Source | 3,484,000Source | 2,885,000Source | 4,016,000Source | 3,808,000Source | 3,847,000Source | 13,340,000Source | 14,066,000Source | 14,764,000Source | 12,751,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 687,000Source | 1,267,000Source | 720,000Source | 754,000Source | 523,000Source | 888,000Source | 2,934,000Source | 5,467,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,353,000Source | -12,747,000Source | -8,185,000Source | -6,462,000Source | -10,028,000Source | -10,649,000Source | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,353,000Source | -12,747,000Source | -8,185,000Source | -6,462,000Source | -10,028,000Source | -10,649,000Source | -35,174,000Source | -51,321,000Source | -64,732,000Source | -42,776,000Source |
| Operating ExpensesUSD | — | — | 10,040,000Source | 14,014,000Source | 8,904,000Source | 7,216,000Source | 10,551,000Source | 11,537,000Source | 38,109,000Source | 56,788,000Source | 69,635,000Source | 42,262,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | -1,000Source | — | — | — | 1,000Source | — | 4,903,000Source | -45,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 2,703,000Source | 22,307,000Source | 46,189,000Source | 46,751,000Source | 132,178,000Source | 93,836,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 38,000Source | 86,000Source | 147,000Source | 366,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 24,000Source | 27,000Source | 27,000Source | 225,000Source | 99,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -10,040,000Source | -14,014,000Source | -8,904,000Source | -7,216,000Source | -10,551,000Source | -11,537,000Source | -38,109,000Source | -56,788,000Source | -69,635,000Source | -42,262,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | -1,000Source | — | — | — | 1,000Source | — | 4,903,000Source | -45,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,353,000Source | -12,747,000Source | -8,185,000Source | -6,462,000Source | -10,028,000Source | -10,649,000Source | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.31Source | -0.43Source | -0.18Source | -0.21Source | -0.29Source | -0.35Source | -1.16Source | -1.72Source | -2.74Source | -2.79Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.31Source | -0.43Source | -0.18Source | -0.21Source | -0.29Source | -0.35Source | -1.16Source | -1.72Source | -2.74Source | -2.79Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 30,276,230Source | 29,841,169Source | 44,760,766Source | 30,172,328Source | 34,059,876Source | 30,053,659Source | 30,215,747Source | 29,828,227Source | 23,600,107Source | 15,340,134Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 30,276,230Source | 29,841,169Source | 44,760,766Source | 30,172,328Source | 34,059,876Source | 30,053,659Source | 30,215,747Source | 29,828,227Source | 23,600,107Source | 15,340,134Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,040,000Source | 3,484,000Source | 2,885,000Source | 4,016,000Source | 3,808,000Source | 3,847,000Source | 13,340,000Source | 14,066,000Source | 14,764,000Source | 12,751,000Source |
| Investment Income, InterestUSD | — | — | 687,000Source | 1,267,000Source | 720,000Source | 754,000Source | 523,000Source | 888,000Source | 2,934,000Source | 5,467,000Source | — | — |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,351,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,353,000Source | -12,747,000Source | -8,185,000Source | -6,462,000Source | -10,028,000Source | -10,649,000Source | -35,174,000Source | -51,321,000Source | -64,732,000Source | -42,776,000Source |
| Operating ExpensesUSD | — | — | 10,040,000Source | 14,014,000Source | 8,904,000Source | 7,216,000Source | 10,551,000Source | 11,537,000Source | 38,109,000Source | 56,788,000Source | 69,635,000Source | 42,262,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,820,000Source |
| Research and Development ExpenseUSD | — | — | 7,000,000Source | 8,287,000Source | 6,019,000Source | 3,200,000Source | 6,743,000Source | 7,690,000Source | 24,769,000Source | 40,488,000Source | 54,871,000Source | 28,511,000Source |
Offerings
Registration 333-294956
Filing attachments
antx-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Advancing startup activities for Phase 2 study of AN2-502998 in chronic Chagas disease AN2-504661 selected as …
Read attachment ↗antx-ex99_1.htm · S-8 · 2026-09-14
Exhibit 99.1 AN2 Therapeutics, Inc. 2026 Employment Inducement Award Plan Adopted by the Board of Directors: August 27, 2026 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through t…
Read attachment ↗antx-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics and safety profile support p…
Read attachment ↗d247428dex991.htm · 8-K · 2026-06-04
EX-99.1 2 d247428dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities Signif…
Read attachment ↗antx-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-huma…
Read attachment ↗d44885dex46.htm · S-3 · 2026-04-09
Exhibit 4.6 AN2 THERAPEUTICS, INC. INDENTURE Dated as of ___________, 20___ [_________] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions …
Read attachment ↗